UCLA Health
At UCLA Health, we provide the best health care, using the latest medical technology — healing humankind one patient at a time.
Oncology
UCLA Health
IASLC TTLC 2025 Insights: TROP-2 ADCs in NSCLC
FEATURING
Aaron Lisberg
- 7 views
- March 20, 2025
UCLA Health
Unmet Treatment Needs of Chemo-IO in Resectable NSCLC
FEATURING
Jay M. Lee
- 64 views
- March 8, 2025
UCLA Health
Current Landscape of Neoadjuvant, Perioperative, and Adjuvant IO in Resectable NSCLC
FEATURING
Jay M. Lee
- 132 views
- March 8, 2025
- 2
UCLA Health
IGCS 2024 Summary and Highlights: Key Trial Insights on Endometrial and Ovarian Cancer
FEATURING
Dana Chase
- 444 views
- December 18, 2024
- 1
UCLA Health
Different Uses of Efanesoctocog Alfa in Hemophilia A: Prophylaxis, Perioperative Use, and On-Demand Bleeding
FEATURING
Doris Quon
- 72 views
- September 23, 2024
- 2
UCLA Health
Best of ASCO® Los Angeles 2024: The PATHWay Trial - Adjuvant Pembro vs. Placebo in Patients With HNSCC at High Risk for Recurrence
FEATURING
Deborah Wong
- 141 views
- September 19, 2024
- 1
UCLA Health
Antibody Drug Conjugates in Gynecologic Oncology: From Bench to Bedside
FEATURING
Gottfried Konecny
- 333 views
- June 14, 2024
- 1
UCLA Health
AACR 2024 Insights: "IMvoke010 - Comparing Atezolizumab to Placebo After Local Therapy in High-Risk Locally Advanced HNSCC"
FEATURING
Deborah Wong
- 159 views
- May 15, 2024
- 1
UCLA Health
HERTHENA-Lung01 Study: Patritumab Deruxtecan as a HER3 Target in EGFRm Advanced NSCLC
FEATURING
Aaron Lisberg
- 166 views
- May 9, 2024
- 1
UCLA Health
Managing Advanced Prostate Cancer Pts in Urology Clinics and When to Refer to Medical Oncologists
FEATURING
Isla Garraway
- 179 views
- March 18, 2024
- 1
UCLA Health
Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Metastatic Pancreatic Cancer
FEATURING
Zev A. Wainberg
- 429 views
- March 8, 2024
- 1
UCLA Health
Y90 Radioembolization for Locally Advanced HCC
FEATURING
Siddharth Padia
- 736 views
- March 1, 2024
- 4
UCLA Health
2024 Updates in Locally Advanced Cervical Cancer
FEATURING
Dana Chase
- 429 views
- February 2, 2024
- 1
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "TROPION-Lung01 Study - Dato-DXd vs. Docetaxel in Previously Treated Advanced/Metastatic NSCLC"
FEATURING
Aaron Lisberg
- 325 views
- November 17, 2023
- 3
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Phase 1b Trial Evaluating the Safety of Ribociclib, Tucatinib, & Trastuzumab for HER2+ mBC & Phase 2 Study of Preoperative Treatment With Ribociclib, Trastuzumab, Tucatinib +/- Fulvestrant vs. Docetaxel, Carboplatin, Trastuzumab, & Pertuzumab for HR+/-, HER2+ BC"
FEATURING
Nicholas McAndrew
- 311 views
- June 29, 2023
- 1
ASH 2022 Conference Coverage
ASH 2022 Once Weekly Selinexor, Carfilzomib & Dexamethasone (XKd) in Triple-Class Refractory MM
FEATURING
Gary Schiller
- 56 views
- December 22, 2022
UCLA Health
Recurrent Cervical Cancer: Updates on Management
FEATURING
Ritu Salani
- 499 views
- April 20, 2022
- 4
UCLA Health
Importance of Thoughtful Testing for PIK3CA Mutations in HR+ MBC
FEATURING
Kelly McCann
- 308 views
- March 14, 2022
- 1
UCLA Health
Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer
FEATURING
Amar Kishan
- 338 views
- December 2, 2021
- 1
UCLA Health
ASCO 2021 Highlights on the Outcomes in Patients ≥ 65 Years in the ASCENT Study of Sacituzumab Govitecan in mTNBC
FEATURING
Sara A. Hurvitz
- 100 views
- October 13, 2021
- 1
i3 Health
Treatment Advances in mTNBC Personalized Care: Clinical & Molecular Factors, Novel Therapies Outcomes, AEs Management Strategies
FEATURING
Sara A. Hurvitz
- 49 views
- August 3, 2021
- 1
UCLA Health
ASCO 2021 Updates on Advanced NSCLC: Dose Analysis of the TROP2-Directed ADC Datopotamab Deruxtecan
FEATURING
Aaron Lisberg
- 110 views
- July 6, 2021
- 1
UCLA Health
A Case of Stage 3 Distal EAC & ESCC: Considering Pembro+dCRT & Tiragolumab+Atezo After dCRT
FEATURING
Zev A. Wainberg
- 25 views
- May 26, 2021
UCLA Health
2021 Updates on Esophageal Cancer: How Important Is Genomic Profiling? How Does Molecular Landscape Look Like?
FEATURING
Zev A. Wainberg
- 255 views
- May 26, 2021
- 1
UCLA Health
Prostate Cancer PET Imaging Biological Target: FACBC vs PSMA PET/CT - Which Option Should Be the Imaging Modality of Choice in Patients With post-RP early BCR? What Is the Best PET Target for Early Biochemical Recurrence of Prostate Cancer?
FEATURING
Jeremie Calais
- 245 views
- July 15, 2020
UCLA Health
PSMA PET Imaging for Primary Staging: Efficacy Analysis of Methods for Ruling-out N1 and M1b Disease?
FEATURING
Jeremie Calais
- 49 views
- July 15, 2020
- 2
UCLA Health
2020 ASCO Update on mCRPC: What Is the OS After 177Lu-PSMA-617 Molecular Radiotherapy?
FEATURING
Jeremie Calais
- 524 views
- June 4, 2020
- 2
UCLA Health
Immunotherapy and Clinical Trials for Brain Tumors
FEATURING
Linda Liau
- 290 views
- January 7, 2020
- 1
UCLA Health
Brain Metastases: Management and Challenging Cases
FEATURING
Won Kim
- 433 views
- January 7, 2020
- 3
UCLA Health
Metastatic Bladder Cancer Beyond Immune Checkpoint Inhibitors: Antibody Drug Conjugates, and Radiation with(out) Anti-PD(L)1
FEATURING
Alexandra Drakaki
- 954 views
- July 10, 2019
- 3
UCLA Health
Metastatic Bladder Cancer Beyond Immune Checkpoint Inhibitors: Chemotherapy Combinations with(out) Anti-PD(L)1
FEATURING
Alexandra Drakaki
- 467 views
- July 10, 2019
- 1